Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study

Table 2 Baseline Cardiac Comorbidities Based on Cardiac Events

Variables	Cardiac Events (N = 11)	No Cardiac Events (N = 79)	p- Value
Hypertension	6 (54.5%)	51 (64.6%)	0.755
Hyperlipidemia	4 (36.4%)	34 (43.0%)	0.925
Diabetes Mellitus	1 (9.1%)	13 (16.5%)	0.851
CAD (Revascularized)	0 (0.0%)	8 (10.1%)	0.589
CHF/ Cardiomyopathy	2 (18.2%)	7 (8.9%)	0.668
Stroke or TIA	0 (0.0%)	2 (2.5%)	1
COPD	1 (9.1%)	1 (1.3%)	0.577
OSA	0 (0.0%)	5 (6.3%)	0.876
PVD	1 (9.1%)	1 (1.3%)	0.577
CKD Stage I-III	1 (9.1%)	0 (0.0%)	0.246
CKD Stage IV-V	0 (0.0%)	1 (1.3%)	1
Atrial Arrhythmia	1 (9.1%)	11 (13.9%)	1
Ventricular Arrhythmia	0 (0.0%)	1 (1.3%)	1
Smoking History			0.973
Past	4 (36.4%)	26 (32.9%)
Never	6 (54.5%)	45 (57.0%)
Current	1 (9.1%)	8 (10.1%)

Data presented as number (percentage)
Abbreviations: CAD: Coronary artery disease, CHF: chronic heart failure, TIA: transient ischemic attack, COPD: chronic obstructive pulmonary disease, OSA: obstructive sleep apnea, PVD: peripheral vascular disease, CKD: chronic kidney disease

ISSN: 2057-3804